For Akebia Therapeutics Inc. [AKBA], Analyst sees a drop to $2. What next?

Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 7.34% on the last trading session, reaching $0.29 price per share at the time. The company report on November 3, 2022 that Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Akebia to host conference call on November 3 at 4:30 p.m. ET.

Filed Formal Dispute Resolution Request related to the CRL for vadadustat.

Akebia Therapeutics Inc. represents 183.60 million in outstanding shares, while the company has a total market value of $54.72 million with the latest information. AKBA stock price has been found in the range of $0.2556 to $0.32.

If compared to the average trading volume of 2.09M shares, AKBA reached a trading volume of 3313220 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Akebia Therapeutics Inc. [AKBA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKBA shares is $1.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKBA stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 31, 2022. The new note on the price target was released on March 31, 2022, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $6 to $2, while Mizuho kept a Neutral rating on AKBA stock. On March 31, 2022, analysts decreased their price target for AKBA shares from 10 to 2.

The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.03, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 0.18. The Price to Book ratio for the last quarter was 0.84.

Trading performance analysis for AKBA stock

Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.01. With this latest performance, AKBA shares dropped by -9.78% in over the last four-week period, additionally sinking by -31.12% over the last 6 months – not to mention a drop of -91.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 48.10, with the RSI for the last a single of trading hit 54.69, and the three-weeks RSI is set at 45.07 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 0.3264, while it was recorded at 0.2672 for the last single week of trading, and 0.8192 for the last 200 days.

Akebia Therapeutics Inc. [AKBA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -124.23 and a Gross Margin at +27.28. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -132.43.

Return on Equity for this stock declined to -174.55, with Return on Assets sitting at -48.36.

Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.

An analysis of insider ownership at Akebia Therapeutics Inc. [AKBA]

There are presently around $17 million, or 33.30% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: VANGUARD GROUP INC with ownership of 16,259,104, which is approximately 12.887% of the company’s market cap and around 0.70% of the total institutional ownership; ACADIAN ASSET MANAGEMENT LLC, holding 7,339,043 shares of the stock with an approximate value of $2.09 million in AKBA stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $1.53 million in AKBA stock with ownership of nearly 103.44% of the company’s market capitalization.

Positions in Akebia Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 40 institutional holders increased their position in Akebia Therapeutics Inc. [NASDAQ:AKBA] by around 18,300,653 shares. Additionally, 82 investors decreased positions by around 40,236,596 shares, while 20 investors held positions by with 282,593 shares. The mentioned changes placed institutional holdings at 58,254,656 shares, according to the latest SEC report filing. AKBA stock had 21 new institutional investments in for a total of 10,275,720 shares, while 47 institutional investors sold positions of 4,929,313 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here